嘉必优: 嘉必优生物技术（武汉）股份有限公司2025年半年度报告摘要

Core Viewpoint - The report highlights the financial performance of Cabio Biotechnology (Wuhan) Co., Ltd. for the first half of 2025, showcasing significant growth in revenue and net profit compared to the previous year. Financial Performance - Total assets at the end of the reporting period reached approximately 1.84 billion RMB, an increase of 12.31% from the previous year-end total of approximately 1.64 billion RMB [1]. - The net profit attributable to shareholders of the listed company was approximately 99.92 million RMB, representing an increase of 88.51% compared to approximately 53.01 million RMB in the same period last year [1]. - Operating revenue for the period was approximately 306.73 million RMB, reflecting a growth of 17.60% from approximately 260.83 million RMB in the previous year [1]. - The total profit for the period was approximately 123.16 million RMB, which is a 57.82% increase from approximately 78.04 million RMB in the same period last year [1]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 8,278 [2]. - The largest shareholder, Wuhan Xinyang Biotechnology Co., Ltd., holds 44.17% of the shares, amounting to 74.34 million shares [2]. - Other notable shareholders include Liu Guoyong with 1.59% (2.68 million shares) and Yi Dewei with 1.39% (2.33 million shares) [2]. Research and Development - The report indicates that the proportion of R&D investment relative to operating revenue is a key focus, although specific percentages are not detailed in the provided text [3].